cANCA in serum; anti-myeloblastin in serum; anti-serine protease 3 in serum
Jump to navigation
Jump to search
Indications
- >90% positive predictive value for Wegener's granulomatosis
- other disorders associated with cANCA include:
Clinical significance
- directed against myeloblastin (serine proteinase-3)
- cANCA may play a role in the pathology of Wegener's granulomatosis (see myeloblastin)
Methods
see anti-neutrophil cytoplasmic antibody (ANCA)
Specimen
store at -20 C
More general terms
More specific terms
Additional terms
- cANCA (anti-myeloblastin, anti-serine protease 3)
- myeloblastin; leukocyte proteinase 3; PR-3; PR3; azurophil granule protein 7; AGP7; Wegener autoantigen; P29; C-ANCA antigen; neutrophil proteinase 4; NP-4 (PRTN3, MBN)
- neutrophil or polymorphonuclear leukocyte (PMN, poly)
References
- ↑ Clinical Guide to Laboratory Tests, NW Tietz (ed) 3rd ed, WB Saunders, Philadelphia 1995
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 782, 847
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 1913
- ↑ Kaiser Permanente Northern Calfornia Regional Laboratory
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, 16, 17. American College of Physicians, Philadelphia 1998, 2012, 2015
- ↑ Bosch X et al, Antineutrophil cytoplasmic antibodies. Lancet 2006, 368:404 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16876669
- ↑ 7.0 7.1 NEJM Knowledge+